Dabigatran | Rivaroxaban | Apixaban | P-value | |
---|---|---|---|---|
3 months | ||||
PDC, mean (SD) | 0.78 (0.27) | 0.81 (0.27) | 0.83 (0.25) | <.0001 |
≥ 0.8, n (%) | 9196 (61.87) | 10,865 (67.89) | 5675 (70.25) | |
0.5–.079, n (%) | 2495 (16.79) | 2188 (13.67) | 1199 (14.84) | |
< 0.5, n (%) | 3173 (21.35) | 2952 (18.44) | 1204 (14.90) | |
Switching, n (%) | 1016 (6.84) | 729 (4.55) | 255 (3.16) | <.0001 |
Warfarin | 611 (4.11) | 414 (2.59) | 118 (1.46) | |
Dabigatran | – | 101 (0.63) | 23 (0.28) | |
Rivaroxaban | 341 (2.29) | – | 114 (1.41) | |
Apixaban | 64 (0.43) | 214 (1.34) | – | |
Gap, n (%) | ||||
≥ 3 days | 7276 (48.95) | 7055 (44.08) | 3662 (45.33) | <.0001 |
≥ 7 days | 6026 (40.54) | 5770 (36.05) | 2892 (35.80) | <.0001 |
≥ 15 days | 4953 (33.32) | 4689 (29.30) | 2262 (28.00) | <.0001 |
6 months | ||||
PDC, mean (SD) | 0.67 (0.33) | 0.72 (0.32) | 0.76 (0.29) | |
≥ 0.8, n (%) | 7156 (52.57) | 8241 (58.49) | 4054 (62.97) | |
0.5–.079, n (%) | 2698 (19.44) | 2491 (17.68) | 1189 (18.47) | |
< 0.5, n (%) | 4023 (28.99) | 3358 (23.83) | 1195 (18.56) | |
Switching, n (%) | 1369 (9.87) | 936 (6.64) | 321 (4.99) | <.0001 |
Warfarin | 778 (5.61) | 523 (3.71) | 155 (2.41) | |
Dabigatran | – | 124 (0.88) | 24 (0.37) | |
Rivaroxaban | 501 (3.61) | – | 142 (2.21) | |
Apixaban | 90 (0.65) | 289 (2.05) | – | |
Gap, n (%) | ||||
≥ 3 days | 9511 (68.54) | 8924 (63.34) | 4230 (65.70) | <.0001 |
≥ 7 days | 8334 (60.06) | 7645 (54.26) | 3520 (54.68) | <.0001 |
≥ 15 days | 7029 (50.65) | 6402 (45.44) | 2829 (43.94) | <.0001 |
9 months | ||||
PDC, mean (SD) | 0.61 (0.35) | 0.67 (0.34) | 0.72 (0.31) | <.0001 |
≥ 0.8, n (%) | 5579 (43.36) | 6260 (51.68) | 2852 (57.70) | |
0.5–.079, n (%) | 2193 (17.04) | 1818 (15.01) | 839 (16.97) | |
< 0.5, n (%) | 5094 (39.59) | 4034 (33.31) | 1252 (25.33) | |
Switching, n (%) | 1590 (12.36) | 990 (8.17) | 299 (6.05) | <.0001 |
Warfarin | 884 (6.87) | 559 (4.62) | 137 (2.77) | |
Dabigatran | – | 121 (1.00) | 23 (0.47) | |
Rivaroxaban | 600 (4.66) | – | 139 (2.81) | |
Apixaban | 106 (0.82) | 310 (2.56) | – | |
Gap, n (%) | ||||
≥ 3 days | 9723 (75.57) | 8593 (70.95) | 3607 (72.97) | <.0001 |
≥ 7 days | 8709 (67.69) | 7553 (62.36) | 3090 (62.51) | <.0001 |
≥ 15 days | 7528 (58.51) | 6445 (53.21) | 2545 (51.49) | <.0001 |
12 months | ||||
PDC, mean (SD) | 0.57 (0.36) | 0.64 (0.36) | 0.70 (0.33) | <.0001 |
≥ 0.8, n (%) | 4761 (40.73) | 5080 (49.83) | 1969 (56.26) | |
0.5–.079, n (%) | 1587 (13.58) | 1284 (12.59) | 498 (14.23) | |
< 0.5, n (%) | 5314 (45.69) | 3831 (37.58) | 1033 (29.51) | |
Switching, n (%) | 1717 (14.69) | 559 (9.41) | 263 (7.51) | <.0001 |
Warfarin | 930 (7.96) | 545 (5.35) | 121 (3.46) | |
Dabigatran | – | 109 (1.07) | 19 (0.54) | |
Rivaroxaban | 663 (5.67) | – | 123 (3.51) | |
Apixaban | 124 (1.06) | 305 (2.99) | – | |
Gap, n (%) | ||||
≥ 3 days | 9350 (79.99) | 7771 (76.22) | 2741 (78.31) | <.0001 |
≥ 7 days | 8475 (72.50) | 6850 (67.19) | 2331 (66.60) | <.0001 |
≥ 15 days | 7428 (63.55) | 5936 (58.22) | 1980 (56.57) | <.0001 |